Volume 4, Issue 4 (12-2020)
EBHPME 2020, 4(4): 234-241 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ranjbar M, Barouni M, Moazed V, Fallahzadeh H, Sheikholeslami S. Survival Rate of Patients with Acute Leukemia: A Case Study in Iran. EBHPME 2020; 4 (4) :234-241
URL: http://jebhpme.ssu.ac.ir/article-1-293-en.html
URL: http://jebhpme.ssu.ac.ir/article-1-293-en.html
Clinical Research Unit, Shahid Bahonar Academic Center, Kerman University of Medical Sciences, Kerman, Iran , Shiva.sh.eslami@gmail.com
Abstract: (2345 Views)
Background: Acute leukemia is a kind of aggressive disease that includes high rates of fatalities in the world, in particular in Iran. This research was done to determine the survival rate of patients with acute leukemia in Iran.
Methods: 85 adult patients who were first diagnosed with acute leukemia in Shahid Bahonar hospital of Kerman during March 2012 until March 2013 were evaluated in a retrospective descriptive study to measure the death/life status in a 5-year period (2012-2017). The required data was gathered from medical records of patients, HIS system data, and the cancer registry system, and the Kaplan-Meier estimator and Log Rank test were used to calculate the survival rate using SPSS23.
Results: Survival rate was completely 45.9 % for patients with acute adult leukemia. It was 47.08 % in acute myelogenous leukemia (AML) and it was 43.06 % in acute lymphocytic leukemia (ALL). The 1,2,3,4 and 5-year survival of acute leukemia was respectively 87.1 %, 69.4 %, 62.4 %, 56.5 % and 45.9 %.
Conclusion: Iran's health system should design and plan to increase the survival of patients with acute leukemia by improving the methods and facilities to diagnose and treat it more quickly and more effectively.
Methods: 85 adult patients who were first diagnosed with acute leukemia in Shahid Bahonar hospital of Kerman during March 2012 until March 2013 were evaluated in a retrospective descriptive study to measure the death/life status in a 5-year period (2012-2017). The required data was gathered from medical records of patients, HIS system data, and the cancer registry system, and the Kaplan-Meier estimator and Log Rank test were used to calculate the survival rate using SPSS23.
Results: Survival rate was completely 45.9 % for patients with acute adult leukemia. It was 47.08 % in acute myelogenous leukemia (AML) and it was 43.06 % in acute lymphocytic leukemia (ALL). The 1,2,3,4 and 5-year survival of acute leukemia was respectively 87.1 %, 69.4 %, 62.4 %, 56.5 % and 45.9 %.
Conclusion: Iran's health system should design and plan to increase the survival of patients with acute leukemia by improving the methods and facilities to diagnose and treat it more quickly and more effectively.
Type of Study: Original article |
Subject:
Healt care Management
Received: 2020/07/2 | Accepted: 2020/12/20 | Published: 2020/12/20
Received: 2020/07/2 | Accepted: 2020/12/20 | Published: 2020/12/20
References
1. 1. Yousefi M, Behzadi Sheikhrobat Y, Najafi S, Ghaffari S, Ghaderi H, Memarzadeh SE, et al. Mapping Catquest Scores onto EQ-5D Utility Values in Patients With Cataract Disease. Iran Red Crescent Med J. 2017; 19(5). [DOI:10.5812/ircmj.21928]
2. Akbarzadeh baghban A, Esmaeili M, Kimiafar K. Medical Information Management and Assessment of Direct Costs of Treatment of Lung Cancer. Health Information Management. 2008; 5(2): 151 - 8.
3. Peter J Dancaab, group. Available from URL: http://www.dadamo.com/science_ABO_cancer.htm. 2019.
4. Vafajo Diantai Z, Abedini Z, Ahmari Tehran H, Mohamadgholizade L. Epidemiology of cancer in Qom, Iran 2008-2011. Health Monitor Journal of the Iranian Institute for Health Sciences Research. 2014; 13(2): 155-63.
5. Jones SB. Cancer in the developing world: a call to action. BMJ. 1999; 319(7208): 505-8. [DOI:10.1136/bmj.319.7208.505]
6. Salehi M, Gohari M, Vahabi N, Zayeri F, Yahyazadeh S, Kafashian M. Comparison of Artificial Neural Network and Cox Regression Models in Survival Prediction of Breast Cancer Patients. Journal of Ilam University of Medical Sciences. 2013; 21(2): 120-8.
7. Fazeli Z, Pourhoseingholi MA, Vahedi M, Abadi A, Bavand-Pour FSF, Baghestani AR. Leukemia cancer mortality trend in Iran, from 1995 to 2004. Iranian Journal of Cancer Prevention. 2013; 6(3): 170.
8. Bahrami M, Moshkani M, Alam Samimi M. Effective Factors on Survival Time of the leukemic Patients and Estimating the Mean of Survival Time by Expectation and Maximization Algorithm and Monte Carlo Markov Chains Simulation Method. Journal of Isfahan Medical School. 2007; 25(84): 49-57.
9. Tahmasebi B, Mahmoudi M, Yahya Pour Y, Jamshidi M, Halakoie Naini K. Determination and comparison of incidence rate and trend of morbidity of leukemia and lymphoma in Mazandaran province. Mazandaran Univ Med Sci. 2006; 16(54): 87-9. [In Persian]
10. Zand A, Imani S, Sa'adati M, Borna H, Ziaei R, Honari H. Effect of age, gender and blood group on blood cancer types. Kowsar Medical Journal. 2010; 15(2): 111-4.
11. Saffar A, Rahgozar M, Shahi F, Biglarian A. Survival analysis of acute myeloid leukemia. Razi Journal of Medical Sciences. 2015; 22(134): 1-48.
12. Mirzaei M, Mirzadeh M, Mirzaei M. Expected Years of Life Lost Due to Adult Cancer Mortality in Yazd ( 2004-2010 ). Asian Pacific Journal of Cancer Prevention : APJCP. 2016; 17(S3): 101-5. [DOI:10.7314/APJCP.2016.17.S3.101]
13. Viscomi S, Pastore G, Dama E, Zuccolo L, Pearce N, Merletti F, et al. Life expectancy as an indicator of outcome in follow-up of population-based cancer registries: the example of childhood leukemia. Ann Oncol. 2006; 17(1): 167-71. [DOI:10.1093/annonc/mdj050]
14. Moradi G, Rasouli MA, Fathi F, Ghaderi B, Nikkhoo B, Roshani D, et al. Evaluation of the survival rate and its related factors in patients with leukemia in Kurdistan Province. Scientific Journal of Kurdistan University of Medical Sciences. 2018; 23(2): 12-20. [DOI:10.29252/sjku.23.2.12]
15. Danese MD, Katz A, Cetin K, Chia V, Gleeson ML, Kelsh M, et al. Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data. Leukemia & Lymphoma. 2019: 1-10. [DOI:10.1080/10428194.2018.1555329]
16. Allahyari A, Hashemi S-M, Nazemian F, Karimi M, Kazemi M-R, Sadeghi M. The Relationship Between Risk Factors and Survival in Adult Acute Lymphoblastic Leukemia. Iranian Journal of Cancer Prevention. 2016; 9(4): 5045. doi: 10.17795/ijcp-5045. [DOI:10.17795/ijcp-5045]
17. Allahyari A, Tajeri T, Sadeghi M. Prognostic Factors and Survival in Acute Myeloid Leukemia Cases: a Report from the Northeast of Iran. Asian Pacific Journal of Cancer Prevention: APJCP. 2016; 17(3): 1547-51. [DOI:10.7314/APJCP.2016.17.3.1547]
18. Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari S, Jahani M, Iravani M, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. Journal of Clinical Oncology. 2011; 29(20): 2753-7. [DOI:10.1200/JCO.2010.32.2107]
19. Ayremlou P, Razavi SM, Solaymani-Dodaran M, Vakili M, Asadi-Lari M. Demographic and prognostic factors of 455 patients with acute leukemia admitted to two referral hospitals in tehran-iran during ten years (2001-2011). Iranian Journal of Cancer Prevention. 2012; 5(3): 157-63
20. Akramipour R, Pedram M, Zandian K, Hashemi A. A 5-Year-study on Children with Acute Myelocytic Leukemia/AML, Ahvaz Shafa Hospital (1996-2001). Journal of Kermanshah University of Medical Sciences. 2007; 11(2): 80674.
21. Askari R, Ranjbar M, Nakhaeizadeh M, Sheikholeslami S, Sepehrifar S, Adhami M, et al. Survival Rate of Patients with Acute Leukemia in Iran: A Systematic Review and Meta-analysis. Evidence Based Health Policy, Management & Economics. 2018; 2(4): 281-9. [DOI:10.18502/jebhpme.v2i4.280]
22. Ashrafi F, Shahnazari R, Samimi MA, Mehrzad V. Results of treatment of acute myeloid leukemia in central part of Iran. Advanced Biomedical Research. 2013; 51-2. [DOI:10.4103/2277-9175.114194]
23. Mashhadi MA, Koushyar MM, Mohammadi M. Outcome of adult acute lymphoblastic leukemia in South East of iran (Zahedan). Iran J Cancer Prev. 2012; 5(3): 130-7.
24. Sayehmiri K, Esgraghian M, Mohammad K, Alimoghaddam K, Rahimi Foroushani A, Zeraati H. Prognostic factors of survival time after hematopoietic stem cell transplant in acute lymphoblastic leukemia patients: Cox proportional hazard versus accelerated failure time models. Journal of Experimental & Clinical Cancer Research. 2008; 27(74). [DOI:10.1186/1756-9966-27-74]
25. Gu B, Chen GH, Shen HJ, Ma X, Fu CC, Han Y, et al. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib]. Zhonghua nei ke za zhi. 2016; 55(4): 293-7.
26. Liu L, Zhang X, Qiu H, Tang X, Han Y, Fu C, et al. HLA-mismatched stem cell microtransplantation compared to matched-sibling donor transplantation for intermediate/ high-risk acute myeloid leukemia. Annals of Hematology. 2019; 98(5): 1249-57. [DOI:10.1007/s00277-018-3583-3]
27. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1): 9-29. [DOI:10.3322/caac.21208]
28. Sankaranarayanan R, Swaminathan R, Lucas E. Cancer survival in Africa, Asia, the Caribbean and Central America: International Agency for Research on Cancer Lyon; 2011.
29. Bouché O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial(8801) Annals of oncology : official Journal of the European Society for Medical Oncology / ESMO. 2005; 16(9): 1488-97. [DOI:10.1093/annonc/mdi270]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
